Skye Bioscience, Inc. recently announced that in a preclinical study assessing the neuroprotective properties of its SBI-100 ophthalmic nanoemulsion, the treated group demonstrated a trend of retaining greater function of the eye’s retinal ganglion cells (RGCs) versus vehicle control. RGCs are cells which process and transmit visual information to the brain.

“There is broad scientific evidence demonstrating the neuroprotective properties of cannabinoids, notably THC, and these results from our proprietary THC-based drug candidate are encouraging,” said Punit Dhillon,

 » Read more about: Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model  »